At the ASCO 2019 annual meeting, Ramon Andrade de Mello discusses the promise of immunotherapies in oesophageal and gastric cancer. Highlighting the need to understand the tumor microenvironment to allow identification of biomarkers to appropriately select the best immune checkpoint inhibitors he also considers the role of combination therapy in improving overall outcomes.
1. What are the limitations of current immunotherapies in oesophageal and gastric cancer? (0:03)
2. How can we optimise the delivery of immunotherapy to overcome immunosuppression in the tumour microenvironment? (1:38)
3. What combined immunotherapy approaches appear most promising for oesophageal and gastric cancer? (2:51)
4. How can we select patients who are most likely to respond to combined immunotherapy approaches? (3:55)
5. What novel approaches are likely to emerge in the near future? (5:03)
Speaker disclosure: Ramon Andrade de Mello has received speaker honoraria from Novartis and AstraZeneca, an educational grant from Merck & Co and participated in advisory boards for MSD, Pfizer and Zodiac.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Gastrointestinal Oncology
Jared Weiss, ESMO 2021: The Efficacy and Safety Findings of the KRYSTAL-1 Study
touchONCOLOGY joins Dr Jared Weiss (UNC Lineburger Comprehensive Cancer Care Center, Chapel Hill, NC, USA) at ESMO 2021 to discuss KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or Combined with Cetuximab (Cetux) in Patients (Pts) With Colorectal Cancer (CRC) Harboring a KRASG12C Mutation. Questions 1. What is the rationale for targeting KRAS tumour mutations in colorectal cancer? […]
Bruno Sangro, EASL ILC 2021: Early Phase Data on Checkpoint Inhibitors in HCC
It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC. Questions Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? […]
Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer
touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!